Safety, tolerability, pharmacokinetic and pharmacodynamic effects of the muscarinic M1 positive allosteric modulator VU0467319 for Alzheimer’s disease: a single ascending-dose study in healthy participants

Safety, tolerability, pharmacokinetic and pharmacodynamic effects of the muscarinic M1 positive allosteric modulator VU0467319 for Alzheimer’s disease: a single ascending-dose study in healthy participants

Abstract The development of cholinergic neurotransmitter based cognitive enhancers for Alzheimer’s disease and other neuropsychiatric disorders have focused recently on allosteric modulation of specific muscarinic acetylcholine receptor (mAChR) subtypes to reduce dose-limiting side-effects that have...

Full description

Saved in:
Bibliographic Details
Main Authors: Alexander C. Conley, Alexandra P. Key, Jennifer U. Blackford, Jason K. Russell, Kimberly M. Albert, Xuewen Gong, Michael Bubser, Jerri M. Rook, P. Jeffrey Conn, Craig W. Lindsley, Carrie K. Jones, Paul A. Newhouse
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Alzheimer’s Research & Therapy
Subjects:
Muscarinic acetylcholine receptor subtype 1 (M1)
Positive allosteric modulator (PAM)
Cognition
Metabolism
Pharmacokinetics
Pharmacodynamics
Online Access:https://doi.org/10.1186/s13195-025-01798-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13195-025-01798-4

Similar Items